COVID A
UTHORS
Online profiles of coronavirus experts
Return to Top
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians. Pulm Pharmacol Ther. 2021 10; 70:102055.
View in:
PubMed
subject areas
Benzamidines
Fibrinolysin
Guanidines
Humans
authors with profiles
Hong-Long Ji
Timothy J Ness
Brant M Wagener
Runzhen Zhao